The main objective of the study is the assessment of the overall graft rejection rate (acute,
chronic and subclinical) between a treatment with ATG-Fresenius administered in addition to
standard treatment consisting of CellCept® or Myfortic®/TAC and without corticosteroids and a
treatment consisting of CellCept® or Myfortic®/TAC and corticosteroids during the first year
after renal transplantation.